The critical role of the bone microenvironment in cancer metastases

Sandra Casimiro, Theresa Guise, John Chirgwin

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Bone metastatic disease is a late-stage event of many common cancers, such as those of prostate and breast. It is incurable and causes severe morbidity. Tumor and bone interact in a vicious cycle, where tumor-secreted factors stimulate bone cells, which in turn release growth factors and cytokines that act back on the tumor cells. Within the vicious cycle are many potential therapeutic targets for novel treatment of bone metastatic disease. Therapeutic strategies can be oriented to inhibit bone cells (osteoclasts and osteoblasts) or tumor responses to factors enriched in the bone microenvironment. Many publications, especially from pre-clinical animal models, show that this approach, especially combination treatments, can reduce tumor burden and tumor-derived bone lesions. This supports a novel paradigm: tumor growth can be effectively inhibited by targeting the bone and its microenvironment rather than the tumor itself alone.

Original languageEnglish (US)
Pages (from-to)71-81
Number of pages11
JournalMolecular and Cellular Endocrinology
Volume310
Issue number1-2
DOIs
StatePublished - Oct 30 2009
Externally publishedYes

Fingerprint

Tumor Microenvironment
Tumors
Bone
Neoplasm Metastasis
Bone and Bones
Neoplasms
Bone Diseases
Osteoclasts
Tumor Burden
Osteoblasts
Publications
Prostate
Intercellular Signaling Peptides and Proteins
Breast
Animal Models
Animals
Cytokines
Morbidity
Cells
Therapeutics

Keywords

  • Bone metastases
  • Bone microenvironment
  • Matrix metalloproteinases
  • Osteoblastic metastases
  • Osteolytic metastases
  • Transforming growth factor beta

ASJC Scopus subject areas

  • Endocrinology
  • Molecular Biology
  • Biochemistry

Cite this

The critical role of the bone microenvironment in cancer metastases. / Casimiro, Sandra; Guise, Theresa; Chirgwin, John.

In: Molecular and Cellular Endocrinology, Vol. 310, No. 1-2, 30.10.2009, p. 71-81.

Research output: Contribution to journalArticle

@article{028c3c70a78044c4a5964147dbb38146,
title = "The critical role of the bone microenvironment in cancer metastases",
abstract = "Bone metastatic disease is a late-stage event of many common cancers, such as those of prostate and breast. It is incurable and causes severe morbidity. Tumor and bone interact in a vicious cycle, where tumor-secreted factors stimulate bone cells, which in turn release growth factors and cytokines that act back on the tumor cells. Within the vicious cycle are many potential therapeutic targets for novel treatment of bone metastatic disease. Therapeutic strategies can be oriented to inhibit bone cells (osteoclasts and osteoblasts) or tumor responses to factors enriched in the bone microenvironment. Many publications, especially from pre-clinical animal models, show that this approach, especially combination treatments, can reduce tumor burden and tumor-derived bone lesions. This supports a novel paradigm: tumor growth can be effectively inhibited by targeting the bone and its microenvironment rather than the tumor itself alone.",
keywords = "Bone metastases, Bone microenvironment, Matrix metalloproteinases, Osteoblastic metastases, Osteolytic metastases, Transforming growth factor beta",
author = "Sandra Casimiro and Theresa Guise and John Chirgwin",
year = "2009",
month = "10",
day = "30",
doi = "10.1016/j.mce.2009.07.004",
language = "English (US)",
volume = "310",
pages = "71--81",
journal = "Molecular and Cellular Endocrinology",
issn = "0303-7207",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - The critical role of the bone microenvironment in cancer metastases

AU - Casimiro, Sandra

AU - Guise, Theresa

AU - Chirgwin, John

PY - 2009/10/30

Y1 - 2009/10/30

N2 - Bone metastatic disease is a late-stage event of many common cancers, such as those of prostate and breast. It is incurable and causes severe morbidity. Tumor and bone interact in a vicious cycle, where tumor-secreted factors stimulate bone cells, which in turn release growth factors and cytokines that act back on the tumor cells. Within the vicious cycle are many potential therapeutic targets for novel treatment of bone metastatic disease. Therapeutic strategies can be oriented to inhibit bone cells (osteoclasts and osteoblasts) or tumor responses to factors enriched in the bone microenvironment. Many publications, especially from pre-clinical animal models, show that this approach, especially combination treatments, can reduce tumor burden and tumor-derived bone lesions. This supports a novel paradigm: tumor growth can be effectively inhibited by targeting the bone and its microenvironment rather than the tumor itself alone.

AB - Bone metastatic disease is a late-stage event of many common cancers, such as those of prostate and breast. It is incurable and causes severe morbidity. Tumor and bone interact in a vicious cycle, where tumor-secreted factors stimulate bone cells, which in turn release growth factors and cytokines that act back on the tumor cells. Within the vicious cycle are many potential therapeutic targets for novel treatment of bone metastatic disease. Therapeutic strategies can be oriented to inhibit bone cells (osteoclasts and osteoblasts) or tumor responses to factors enriched in the bone microenvironment. Many publications, especially from pre-clinical animal models, show that this approach, especially combination treatments, can reduce tumor burden and tumor-derived bone lesions. This supports a novel paradigm: tumor growth can be effectively inhibited by targeting the bone and its microenvironment rather than the tumor itself alone.

KW - Bone metastases

KW - Bone microenvironment

KW - Matrix metalloproteinases

KW - Osteoblastic metastases

KW - Osteolytic metastases

KW - Transforming growth factor beta

UR - http://www.scopus.com/inward/record.url?scp=69249206543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249206543&partnerID=8YFLogxK

U2 - 10.1016/j.mce.2009.07.004

DO - 10.1016/j.mce.2009.07.004

M3 - Article

C2 - 19616059

AN - SCOPUS:69249206543

VL - 310

SP - 71

EP - 81

JO - Molecular and Cellular Endocrinology

JF - Molecular and Cellular Endocrinology

SN - 0303-7207

IS - 1-2

ER -